<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923738</url>
  </required_header>
  <id_info>
    <org_study_id>WP41152</org_study_id>
    <secondary_id>2018-004718-17</secondary_id>
    <nct_id>NCT03923738</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).</brief_title>
  <official_title>A Phase Ib, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Administered by Intravenous Infusion to Patients With Giant Cell Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose
      levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to
      participants with giant cell arteritis (GCA).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of TCZ</measure>
    <time_frame>Days 1, 57, 85, 113, 120, 127, 134, 141, 197, 225, 253, 260, 267, 274 and 281</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Serum Concentration (Ctrough) of TCZ</measure>
    <time_frame>Days 1, 57, 85, 113, 120, 127, 134, 141, 197, 225, 253, 260, 267, 274 and 281</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve over the Dosing Interval of 4 Weeks (AUC4weeks) of TCZ</measure>
    <time_frame>Days 1, 57, 85, 113, 120, 127, 134, 141, 197, 225, 253, 260, 267, 274 and 281</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>From Baseline through Day 281</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Interleukin-6 (IL-6)</measure>
    <time_frame>On Days 1, 85, 113, 141, 225, 253 and 281</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R)</measure>
    <time_frame>On Days 1, 85, 113, 141, 225, 253 and 281</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of C-Reactive Protein (CRP)</measure>
    <time_frame>At screening, Days 1, 29, 57, 85, 113, 120, 127, 134, 141, 169, 197, 225, 253, 260, 267, 274 and 281</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>At screening, Days 1, 29, 57, 85, 113, 120, 127, 134, 141, 169, 197, 225, 253, 260, 267, 274 and 281</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>RoActemra/Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of GCA as classified according to protocol-specified criteria;

          -  Participants entering Period 1 must be receiving treatment with TCZ 8 mg/kg IV Q4W.

        Exclusion Criteria:

          -  Treatment with any other investigational agent besides TCZ within 12 weeks (or 5
             half-lives of the investigational drug, whichever is longer) prior to screening;

          -  Evidence of serious uncontrolled disease;

          -  Known active current or history of recurrent bacterial, viral, fungal, mycobacterial,
             or other infections;

          -  Active TB requiring treatment within the previous 3 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universit√§tsspital Basel; Rheumatologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern; Rheumatologie; Klinische Immunologie und Allergologie</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

